J Pathol Clin Res September 2022; 8: 422–435 Published online 16 June 2022 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/cjp2.281

Tertiary lymphoid structures favor outcome in resected esophageal squamous cell carcinoma

Rutao Li^{1,2,3†}, Xing Huang^{4†}, Wenmin Yang^{1,2,3†}, Jifan Wang^{1,2}, Yingkuan Liang^{1,2}, Te Zhang^{1,2,3}, Qixing Mao^{1,2}, Wenjie Xia^{1,2}, Lin Xu^{1,2,3,5}, Xinyu Xu^{4*}, Gaochao Dong^{1,2*} and Feng Jiang^{1,2,3*}

¹Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, PR China

²Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Cancer Institute of Jiangsu Province, Nanjing, PR China

³The Fourth Clinical College of Nanjing Medical University, Nanjing, PR China

⁴Department of Pathology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, PR China

⁵Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, PR China

*Correspondence to: Feng Jiang, Department of Thoracic Surgery, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, PR China. E-mail: fengjiang_nj@njmu.edu.cn, Gaochao Dong, Department of Thoracic Surgery, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, PR China. E-mail: ilsyvm@njmu.edu.cn, and Xinyu Xu, Department of Pathology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, PR China. E-mail: xxyblk@163.com

[†]These authors contributed equally to this work.

Abstract

Tertiary lymphoid structures (TLSs) are considered to have a good prognosis in multiple solid tumors. However, the prognostic value of TLS in esophageal squamous cell carcinoma (ESCC) is unknown. In this study, we retrospectively enrolled 185 ESCC patients who underwent surgical resection. Hematoxylin and eosin staining was performed to investigate the presence, the abundance, the maturation, and the location of TLSs. We explored the cellular composition of TLSs using traditional immunohistochemistry in serial sections. The prognostic value of TLSs was investigated by univariate and multivariate analyses. A nomogram was constructed to predict the prognosis. TLS-positive tumors were infiltrated with more CD45⁺ leukocytes, CD20⁺ B cells, CD4⁺ and CD8⁺ T cells, and CD11c⁺ dendritic cells (DCs) compared with negative tumors. Kaplan–Meier curves showed that the presence and the abundance of TLSs were associated with longer disease-free survival (DFS) (p = 0.0130) and overall survival (OS) (p = 0.0164). In addition, patients with tumors containing more CD20⁺ B cell infiltration had longer DFS (p = 0.0105) and OS (p = 0.0341). Multivariate analyses demonstrated that the presence of TLSs was an independent prognostic factor for DFS (hazard ratio [HR] = 0.384, p < 0.001) and OS (HR = 0.293, p < 0.001). The nomogram that integrated the tumor stage, histologic grade, and TLS presence had higher prognostic accuracy. Our study suggests that ESCC-related TLSs can be used as a new biomarker for the prognosis of ESCC patients, and further understanding of their formation and mechanism of induction can provide a possible direction and target for immunotherapy of ESCC.

Keywords: tertiary lymphoid structure; esophageal squamous cell carcinoma; prognostic value; immunotherapy target

Received 19 February 2022; Revised 23 April 2022; Accepted 10 May 2022 No conflicts of interest were declared.

Introduction

Esophageal cancer is the seventh most common cancer and sixth leading cause of cancer-related mortality worldwide; the major histologic subtype is esophageal squamous cell carcinoma (ESCC), which has a particularly high incidence in Eastern Asia and in Eastern and Southern Africa [1]. Clinical outcomes of ESCC remain poor, despite advances in surgical treatments over the past few decades [2]. Recently, patients with

© 2022 Nanjing Medical University. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland and John Wiley & Sons Ltd.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

advanced or metastatic ESCC who received camrelizumab (an anti-programmed death receptor 1 [PD-1] antibody) added to chemotherapy were shown to have significantly improved overall survival (OS) and progression-free survival, compared with placebo and chemotherapy [3], which revolutionized the treatment of ESCC. The success of immunotherapy in ESCC underscores the need to better understand the tumor microenvironment that leads to effective antitumor response. T cells have been considered the major immune cells able to induce tumor regression: however, recent publications focused on tertiary lymphoid structures (TLSs) have indicated that they may also play a prominent role in immunotherapy [4].

TLSs are ectopic lymphoid structures that develop in inflamed tissues, such as in chronic infections, autoimmune diseases, and cancers, and are important elements of the tumor-immune microenvironment [5]. In addition to T cells, TLSs are mainly composed of B cells and follicular dendritic cells (FDCs), fibroblast reticular cells, stromal cells, dendritic cells, neutrophils, macrophages, and endothelial cells. FDCs are usually located in the center of B cells and express various receptors that facilitate antigen presentation to B cells; they also promote the expression of highly active antibodies by B cells [6]. The composition of TLSs can synergistically improve the immune response of the body and promote the killing of tumors, but some of the high-depletion molecules, such as PDL1, Treg cells, and myeloid-derived suppressor cells, can also inhibit immunity to varying degree. TLSs predict favorable prognosis in most solid cancers, including pancreatic cancer [7], colorectal cancer [8], and gastrointestinal stromal tumors [9]. However, there were very few studies on ESCC addressing the prognostic and predictive values of TLS and it is not clear whether TLSs could furnish additional value in predicting the survival of ESCC patients.

In this study, we evaluated the presence, abundance, maturation, and location of TLSs in a cohort of 185 patients with primary ESCC treated by surgical resection. These were randomly divided into a discovery cohort with 122 patients and a validation cohort with 63 patients. Here, we aimed to study the prognostic significance of TLSs in ESCC and explore their association with tumor-infiltrating immune cells in this tumor type.

Materials and methods

Patients and samples

A total of 185 patients who underwent surgical resection and histopathologic diagnosis for ESCC at The

Affiliated Cancer Hospital of Nanjing Medical University between January 2017 and December 2018 were included. The patients' inclusion criteria were as follows: (1) pathologically diagnosed as primary ESCC; (2) no chemotherapy or radiotherapy performed before surgery; (3) sufficient preservation of the paraffin-fixed tissue, with clear structure: and (4) the presence of a complete medical treatment record and follow-up information, with a follow-up time longer than 2 years. For all patients, pathologic stages were defined according to the eighth edition of the American Joint Committee on Cancer (AJCC) cancer staging manual using the available clinical and pathologic tumor, node, and metastasis data. Patient information, including age and gender, and clinicopathologic characteristics, such as tumor size and histologic grade, were also collected. Disease-free survival (DFS) was defined as the time from the date of surgery to the date of recurrence. OS was defined as the time from the date of surgery to the date of either death or the last followup. All patients were randomly divided into a discovery cohort (n = 122) and a validation cohort (n = 63). The study was approved by the Ethics Committee of The Affiliated Cancer Hospital of Nanjing Medical University. Samples were obtained from biobank of Jiangsu Cancer Hospital (Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University). All patients had signed informed consent for donating their samples.

H&E staining

The paraffin-embedded human ESCC tissue specimens were cut into 5- μ m serial sections. The sections were dewaxed and rehydrated with xylene and ethanol, respectively, followed by staining with hematoxylin for 5 min and 1% acid ethanol for 3 s. The sections were then rinsed in distilled water and stained with eosin for 3 min. Dehydration and hyalinization were then subsequently performed. Sections were visualized using a light microscope (Nikon, Tokyo, Japan).

IHC staining

The formalin-fixed paraffin-embedded ESCC tissue specimens were cut as serial 5- μ m sections. The sections were deparaffinized in xylene and hydrated through an ethanol series. The sections were then boiled for 5 min in citrate buffer (pH 6.0) and left to cool in order to retrieve epitopes. After quenching endogenous peroxidase with 3% hydrogen peroxide for 15 min, nonspecific binding was blocked by incubating the sections in 10% horse serum, followed by

© 2022 Nanjing Medical University. *The Journal of Pathology: Clinical Research* published by The Pathological Society of Great Britain and Ireland and John Wiley & Sons Ltd.

incubation with primary antibodies at 4 °C overnight. The sections were then rinsed and incubated with appropriate biotinylated secondary antibodies for 30 min at 37 °C, and then rinsed again and incubated with peroxidase-conjugated streptavidin for 30 min at 37 °C. Finally, the sections were reacted with diaminobenzidine solution for 5 min, followed by counterstaining with hematoxylin. The sections were viewed and photographed with a light microscope reacted streptavidin for solution for 5 min and solution for 5 min and

(Nikon). Immunohistochemistry (IHC) was performed to detect CD45, CD20, CD4, CD8, CD11c, and CD68 expression in patient samples using a standard protocol. The antibodies and conditions used in IHC are summarized in supplementary material, Table S1.

Evaluation of TLS and IHC

TLSs are organized aggregates of immune cells that form postnatally in non-lymphoid tissues and arise in the context of chronic inflammation, such as in autoimmune disease, chronic infection, and cancer [10]. On hematoxylin and eosin (H&E)-stained slides, TLSs were identified morphologically as distinct ovoid lymphocytic aggregates containing high endothelial venules and/or a germinal center [11]. The presence, abundance, location, and subtypes of TLS were assessed on H&Estained slides, which were reviewed by two independent pathologists without any clinical information about the patient. Where the assessment was controversial, a third pathological reviewer was involved in a discussion to resolve differences. Before screening the H&Estained slides, the two pathologists agreed on the definition and classification of TLSs, and most of the results were consistent. TLSs were evaluated on whole H&E sections in all the available tumor blocks of each patient. The maximum number of TLSs was selected to define the TLS abundance of the patient [12]. After all TLSs were marked by the pathologist, Xing Huang and Jifan Wang recorded and counted all TLSs in the entire pathological section. After counting and analyzing the TLS abundance of all patients, we defined the TLS-high group as the abundance of TLS more than median 4 and TLS-low group as less than or equal to median 4 [13]. Among the tumors with more than one TLS, we used the maximum number of mature TLSs to categorize the tumor. We defined the location with the greatest number of TLSs as the location of TLSs for this patient. We first performed H&E staining to assess the presence of TLSs in ESCC specimens. Then, TLSs observed around the tumor tissue or in the peritumoral area were defined as peritumoral TLS (supplementary material, Figure S1A) and TLSs within the tumor tissue were defined as intratumoral TLS (supplementary material,

Figure S1B). Tumor-infiltrating TLS were divided into three categories according to the morphology determined by H&E staining; (1) TLS aggregates (AGG): small, quasi-circular clusters of lymphocytes (Figure 1A); (2) TLS follicles 1 (FL-I): large clusters without germinal center formation (Figure 1B); and (3) TLS follicles 2 (FL-II): large clusters with germinal center formation (Figure 1C). In serial sections, the percentage of staining area of each immune cell type in the entire pathological section was used as the degree of infiltration of the immune cell for subsequent analysis.

Statistical analyses

All statistical analyses were performed using SPSS version 26 (SPSS, Chicago, IL, USA) and GraphPad Prism 8 (GraphPad Software Inc., La Jolla, CA, USA). The Wilcoxon signed-rank test, Mann–Whitney test, Spearman correlation, and log-rank test were used, as appropriate. Multivariate analyses were performed using Cox proportional hazards regression to identify independent prognostic factors. Kaplan–Meier analysis was used to compare differences after curative surgery for patient DFS and OS. All tests were two-sided and were performed with a significance level of $\alpha = 0.05$.

Results

Patient characteristics and TLS status in ESCC

In this study, we retrospectively enrolled 185 patients who met the inclusion criteria and divided them randomly into two cohorts; 122 patients were included in the discovery cohort and the other 63 patients in the validation cohort. The detailed clinical characteristics of these two patient cohorts are summarized in Table 1, and no obvious differences were found in the clinical characteristics between the two cohorts. We evaluated the presence and maturation of TLSs (defined in Materials and methods section) and identified them in 89 patients (73.0%) in the discovery cohort. Among patients with TLSs, the maximum degree of TLS maturation was AGG, FL-I, and FL-II in 20 (16.4%), 41 (33.6%), and 28 (23.0%) cases, respectively (Figure 1D, left). In the validation cohort, 47 patients (74.6%) were considered positive with TLS, and the distribution of TLS maturation was similar to that in the discovery cohort, among which the maximum degree was 14 (22.2%), 20 (31.8%), and 13 (20.6%) patients with AGG, FL-I, and FL-II, respectively (Figure 1D, right). The location of TLSs (defined in Materials and methods section) was also evaluated. Among positive patients in the discovery



Figure 1. The classification of TLS in ESCC. (A) Representative H&E image of TLS Aggregates patients. (B) Representative H&E image of TLS Follicles I patients. (C) Representative H&E image of TLS Follicles II patients (red arrow: germinal center). (D) TLS phenotype and frequency evaluated in discovery (left) and validation cohorts (right). Proportions of TLS Negative, TLS Aggregates, Follicle I, and Follicle II in ESCC were summarized by pie chart.

Table	1. Clinicopathologi	c characteristics of	patients in discover	v and validation	cohorts

VariablesNo. (%)No. (%)PolueGender		Discovery cohort ($n = 122$)	Validation cohort ($n = 63$)	
Generic0.0 (53.6)0.1 (2005)0.0 (1000)Mate0.0 (53.6)0.0 (1000)0.0 (1000)Age (year)0.0 (1000)0.0 (1000)0.0 (1000)Smoke0.0 (1000)0.0 (1000)0.0 (1000)Non-smoking0.0 (1000)0.0 (1000)0.0 (1000)Non-smoking0.0 (1000)0.0 (1000)0.0 (1000)Non-smoking0.0 (1000)0.0 (1000)0.0 (1000)Non-smoking0.0 (1000)0.0 (1000)0.0 (1000)Site0.0 (1000)0.0 (1000)0.0 (1000)0.0 (1000)Site (mm)0.0 (1000)0.0 (1000)0.0 (1000) <tr< th=""><th>Variables</th><th>No. (%)</th><th>No. (%)</th><th><i>P</i> value</th></tr<>	Variables	No. (%)	No. (%)	<i>P</i> value
Male10 (B3.61)51 (B0.95)Female20 (16.39)12 (19.05)Agc (vers)67 (71.31)47 (74.60)SR087 (71.31)47 (74.60)SR087 (71.31)47 (42.80)SR087 (14.36)77 (42.80)SR059 (48.36)77 (42.80)SR059 (48.36)77 (42.80)Dinking52 (42.62)42 (30.10)Non-minking70 (57.38)39 (61.90)SR059 (48.36)26 (39.68)SR110 (15.88)10 (15.88)SR156 (48.26)26 (39.68)SR156 (48.26)26 (39.68)SR156 (48.26)26 (39.68)SR257 (46.72)59 (38.61)Jande57 (46.72)59 (36.61)Jande70 (57.38)26 (39.78)Jande71 (45.68)21 (19.05)Jande71 (46.72)25 (39.68)SR230 (36.72)30 (46.72)Jande71 (46.72)25 (39.68)Jande31 (25.41)21 (30.33)Jande31 (25.41)23 (33.31)Jande31 (25.41)23 (33.31)Jande31 (25.41)30 (47.62)Jande31 (25.41)30 (47.62)Jande31 (25.61)30 (47.62)Jande32 (27.63)30 (47.62)Jande32 (27.63)30 (47.62)Jande32 (27.63)30 (47.62)Jande32 (27.63)30 (47.62)Jande32 (27.63)30 (47.62)Jande32 (27.63) <td>Gender</td> <td></td> <td></td> <td>0.651</td>	Gender			0.651
Fende20 (6.39)12 (19.05)Ace (vars)6035 (52.6)16 (25.40)>50036 (71.3)77 (42.60)0.477Smoking59 (48.36)72 (42.62)43 (30.1)Drink	Male	102 (83.61)	51 (80.95)	
Ape (peers)	Female	20 (16.39)	12 (19.05)	
sol35 (23.8)16 (25.40)Sroki7 (74.80)0.477Sroking50 (43.8)7 (74.80)Non-snoking63 (51.64)36 (57.14)Drink0.5339 (61.90)Non-snoking70 (57.38)39 (61.90)Non-cintriking52 (42.62)24 (38.10)Non-cintriking70 (57.38)93 (61.90)Site0.115.800.111.80Upper8 (6.56)10 (15.80)Lower55 (46.32)25 (35.68)Lower55 (46.72)25 (35.68)Site (mm)0.5120.512Site (mm)0.5230.512Site (mm)0.5230.512Site (mm)0.5120.512Site (mm)0.512 </td <td>Age (years)</td> <td></td> <td></td> <td>0.635</td>	Age (years)			0.635
>D027 (1.31)47 (7.460)Smoke0.477Smoking59 (48.36)27 (42.46)Non-smoking63 (51.64)36 (57.14)Drink20 (57.38)39 (61.90)Site0.1110.15.38Upper8 (5.56)22 (44.41)Site0.15.380.111Site0.15.380.111Site0.15.380.111Site0.1110.111Site0.112 <td< td=""><td>≤60</td><td>35 (28.36)</td><td>16 (25.40)</td><td></td></td<>	≤60	35 (28.36)	16 (25.40)	
Smoking 59 (84.36) 27 (42.86) 74 (42.86) Non-smoking 53 (51.64) 36 (57.14) 0.553 Drinking 72 (42.82) 24 (38.10) 0.553 Non-smoking 70 (57.38) 39 (61.90) 0.111 Upper 8 (65.65) 10 (15.88) 0.111 Upper 8 (65.65) 26 (44.44) 0.553 Swoker 55 (45.08) 28 (44.44) 0.361 Swoker 55 (45.08) 28 (45.08) 0.117 Swoker 10 (15.58) 12 (18.06) 0.117 1 19 (15.58) 12 (18.06) 0.256 Swoker 9 (74.672) 25 (35.88) 0.021 1 19 (15.58) 12 (18.05) 0.021 2 49 (40.16) 32 (50.79) 3 3 3 (42.56) 12 (18.05) 0.021 1 19 (15.28) 12 (18.05) 0.256 Yes 9 (74.59) 42 (66.67) 0.021 No 3 (125.41) 32 (53.33) 0.172	>60	87 (71.31)	47 (74.60)	
Smexing59 (43.8)22 (42.62)36 (57.14)Drinking52 (42.62)24 (38.10)	Smoke			0.477
Non-smoking 63 (s1.6.4) 36 (s7.1.4) 0.553 Drinking 70 (s7.38) 38 (s1.00) 0.553 Non-drinking 70 (s7.38) 38 (s1.00) 0.553 Site (s1.58) 0.513 0.513 Upper 8 (s5.65) 10 (t5.88) 0.053 Lower 55 (48.76) 25 (39.68) 0.053 Site (mm) 0.513 0.053 0.053 Site (mon) 10 (19.05) 0.011 0.011 Site (mon) 10 (19.05) 0.011 0.011 Site (mon) 12 (19.05) 0.011 0.011 Site (mon) 13 (25.41) 23 (03.01 0.011 Site (mon) 13 (25.41) 23 (03.01 0.011 Non (sig (29.51) 30 (47.62) 0.011	Smoking	59 (48.36)	27 (42.86)	
Drink mag 52 (42.62) 24 (38.10) 0.553 Drinking 72 (57.38) 29 (61.90) 0.111 Upper 8 (6.56) 10 (15.88) 0.853 Middle 59 (48.36) 25 (39.68) 0.853 Middle 59 (48.36) 28 (44.44) 0.861 Size (mm) 38 (60.32) 0.177 0.177 340 55 (53.28) 38 (60.32) 0.177 1 1 (1 (5.88) 12 (19.05) 0.177 1 1 (1 (1 (5.81)) 12 (1 (1 (5.77)) 0.061 2 49 (40.16) 32 (50.79) 0.062 2 49 (40.16) 32 (50.79) 0.062 3 12 (54.1) 32 (33.3) 0.062 1 10 (8.20) 5 (7.94) 0.062 1 10 (8.20) 5 (7.94) 0.062 1 10 (8.20) 5 (7.94) 0.062 1 10 (8.20) 5 (7.94) 0.062 1 10 (8.20) 5 (7.94) 0.062 1	Non-smoking	63 (51.64)	36 (57.14)	
Drinking 52 (42.62) 24 (38.10) Interpret of the second	Drink			0.553
Non-drinking 70 (57.38) 39 (61.90) Site 0.111 Upper 8 (6.56) 10 (15.88) 25 Middle 59 (48.36) 25 (39.68) 30 Lower 56 (45.68) 28 (44.44) 0.361 Site (mm) 0.361 38 (60.32) 0.37 >40 65 (53.28) 38 (60.32) 0.37 >40 65 (53.28) 38 (60.32) 0.37 21 2 (19.05) 32 (19.05) 0.37 2 39 (25.91) 32 (19.05) 0.37 3 4 (44.61) 32 (19.05) 0.082 23 4 (44.61) 32 (13.33) 0.37 30 5 (7.94) 33 (12.541) 32 (13.33) 0.362 10 0 (8.20) 5 (7.94) 0.082 11 36 (22.51) 30 (47.62) 0.268 11 36 (22.51) 30 (14.762) 0.278 11 36 (23.51) 31 (14.05) 0.39 11 36 (23.65) 12 (19.65)	Drinking	52 (42,62)	24 (38.10)	
Nite 0.0000 0.0000 0.0000 Upper 8 (6.56) 0.0 (15.88) 0.0000 Uwwer 55 (45.08) 28 (24.44) 0.0000 Size (mm) 0.0000 0.0000 0.0000 >40 65 (53.28) 38 (80.63) 0.0000 >40 65 (53.28) 38 (80.63) 0.0000 2 49 (40.16) 32 (50.79) 0.0000 3 54 (44.26) 19 (30.16) 0.0000 1 19 (15.58) 12 (19.05) 0.0000 2 49 (40.16) 32 (50.79) 0.0000 3 54 (44.26) 19 (30.16) 0.0000 1 10 (8.20) 5 (7.94) 0.0000 3 10 (8.20) 5 (3.96.8) 0.0000 1 10 (8.20) 5 (3.96.8) 0.0000 1 10 (8.20) 5 (3.96.8) 0.0000 1 10 (8.20) 5 (3.96.8) 0.0000 1 10 (8.20) 5 (3.96.8) 0.0000 1	Non-drinking	70 (57 38)	39 (61 90)	
Jupper 8 (6.56) 10 (15.8) C111 Middle 59 (46.36) 25 (39.68)	Site	70 (37.30)	33 (01.30)	0 1 1 1
bpin 50 (6.0.0) 0 (10.0.0) Middle 59 (46.36) 25 (33.68) Lower 55 (45.08) 26 (44.44) 572 (fmm) 0.017 540 65 (53.28) 38 (60.32) Histologic grade 0.177 1 19 (15.58) 12 (19.0.5) 2 49 (40.16) 32 (50.79) 3 54 (44.26) 19 (30.16) Lymph node 0.023 (57.74) 0.082 Yes 91 (74.59) 42 (65.67) No 31 (25.41) 32 (33.63) Itmor stage 0.082 17 (74) It 10 (82.0) 5 (77.94) It 3 (42.51) 30 (47.62) IV 5 (41.0) 3 (4.76) IT 23 (18.85) 12 (19.05) IV 5 (41.0) 3 (4.76) IT 23 (18.85) 12 (19.0.5) IV 5 (41.0) 3 (4.76) IV 5 (41.0) 3 (4.76) IV 28 (22.95) 14 (22.20)	Upper	8 (6 56)	10 (15.99)	0.111
Midde 53 (46.36) 24 (34.44) Lower 53 (46.36) 26 (44.44) Size (mm) 0.61 <40	Middle	6 (0.50) F0 (49.30)	10 (13.00)	
Luwr Si (%5.0) 2 (%4.4) ≤40 57 (45.72) 25 (39.68) >40 65 (53.28) 38 (60.32) Histologic grade 0.177 1 19 (15.58) 12 (19.05) 3 54 (44.26) 19 (01.6) 3 54 (44.26) 19 (01.6) 1 91 (74.59) 42 (66.67) 1 10 (8.20) 5 (7.94) No 31 (25.41) 32 (33.33) Tumor stage 008 (20.51) 30 (47.62) III 10 (8.20) 25 (39.68) 12 (19.05) V 5 (4.10) 3 (4.76) 72.88 pT 71 (58.20) 25 (39.68) 12 (19.05) T1 53 (15.656) 0.028 pN 0.38 0.47 (50.66) 35 (55.56) pN 0.38 0.47 (50.60) 72 (28.93) N1 56 (45.90) 17 (26.89) 71 (19.00) N2 28 (22.95) 14 (22.22) 14 (22.22) N3 56 (45.90) 17 (26.89) <td></td> <td>55 (46.50) FF (4F 00)</td> <td>25 (39.00)</td> <td></td>		55 (46.50) FF (4F 00)	25 (39.00)	
Sh2 (mm) 0.35 (96.63) 0.36 (97.64) >40 65 (53.28) 38 (60.32) Histologic grade 0.177 1 19 (15.58) 12 (19.05) 2 49 (40.16) 32 (50.79) 3 54 (42.66) 19 (30.16) Lymph node 0.256 Yes 91 (74.59) 42 (66.67) No 31 (25.41) 32 (33.3) Tumor stage 0.082 1 I 10 (8.20) 5 (9.68) IN 36 (29.51) 30 (47.62) II 36 (29.51) 30 (47.62) IV 5 (4.10) 34 (4.76) IZ 25 (20.49) 16 (25.40) T3 37 (20.66) 35 (55.56) IN 5 (4.10) 3 (4.76) N0 34 (27.05) 49 (46.03) N1 5 (4.10) 3 (4.76) N2 2		55 (45.08)	28 (44.44)	0.001
>40 5/ (46.72) 25 (39.68) >40 65 (53.28) 38 (60.32) Histologic grade 0.177 1 19 (15.58) 32 (50.79) 3 0.54 (44.26) 19 (30.16) Lymph node 0.256 0.253,033 Yes 91 (74.59) 42 (66.67) No 31 (25.41) 32 (33.33) Tumor stage 0.82,03 0.82,03,03 II 10 (8.20) 5 (7.94) III 36 (29.51) 30 (47.62) IV 71 (58.20) 25 (39.68) V 72 (86.66) 70,03 IV 71 (58.20) 25 (39.68) V 72 (86.66) 70,03 IV 74 (60.66) 35 (55.56) IV 23 (18.85) 12 (19.05) IV 24 (60.66) 35 (55.56) IV 29 (46.03) 74 (60.66) N0 33 (27.05) 29 (46.03) N1 56 (45.90) 17 (26.38) N2 28 (22.95) 14	Size (mm)			0.361
>40 65 (32.8) 36 (60.32) Histologic grade 0.777 1 19 (15.58) 12 (19.05) 2 49 (40.16) 32 (50.79) 3 54 (44.26) 19 (30.16) Lymph node 0.256 0.774) Yes 31 (25.41) 32 (33.3) Tumor stage 0.08(20, 57.94) 0.082 I 0.62(25.1) 30 (47.62) II 36 (29.51) 30 (47.62) II 33 (27.63) 29 (46.03) IZ 23 (18.85) 12 (19.05) IZ 23 (18.63) 29 (46.03) IZ 20 (31.75) 37 NO 33 (27.05) 29 (46.03) N1 56 (45.90) 14 (22.22) N3 5 (14.10) 3 (62.5) No 29 (31.97) 20 (31	≤40	57 (46.72)	25 (39.68)	
Histogic grade 0.173 1 19 (15.58) 12 (19.05) 2 49 (40.16) 32 (50.79) 3 0.54 (44.26) 19 (30.16) Lymph note 0.256 Yes 91 (74.59) 42 (66.67) No 31 (25.41) 32 (33.3) Tumor stage 0.082 I 10 (8.20) 5 (7.94) III 36 (29.51) 30 (47.62) III 36 (29.51) 30 (47.62) III 71 (58.20) 25 (39.68) V 5 (14.01) 34 (47.6) T2 23 (18.85) 12 (19.05) T2 23 (18.85) 12 (19.05) T2 23 (18.65) 16 (25.40) T3 74 (60.66) 35 (55.66) pN 0.038 0.702 N0 33 (27.05) 29 (46.03) N2 28 (22.95) 14 (22.22) N2 28 (22.95) 16 (25.40) N2 28 (22.95) 16 (25.40) No 39 (31.97) 20 (31.75) No 36 (80.3) 34 (>40	65 (53.28)	38 (60.32)	
1 19 (15.58) 2 (19.05) 2 49 (40.16) 32 (50.79) 3 54 (44.26) 19 (30.16) Lymph node 0 22 (33.33) Ves 91 (74.59) 42 (66.67) No 31 (25.41) 32 (33.33) Tumor stage 0 0 (8.20) 5 (7.94) II 10 (8.20) 25 (39.68) 0 V 5 (4.10) 30 (47.62) 0 V 5 (4.10) 3 (47.62) 0 T1 22 (18.65) 12 (19.05) 0 T2 22 (18.05) 12 (19.05) 0 T3 0 (666) 35 (55.56) 0 T3 25 (20.49) 16 (25.40) 0 T4 28 (20.55) 12 (19.05) 0 N0 33 (27.05) 29 (46.03) 0 N1 5 (45.90) 17 (26.98) 0 N2 28 (22.95) 14 (22.22) 0 N3 5 (45.90) 17 (26.98) 0 N4 5 (25.95) 16 (25.40) 0 N0	Histologic grade			0.177
2 49 (40.16) 32 (50.79) 3 54 (44.26) 19 (30.16) Lymph node 0.256 Yes 91 (74.59) 42 (66.7) Tumor stage 0.82 I 10 (8.20) 5 (7.94) Umor stage 0.82 I 10 (8.20) 25 (39.68) II 36 (29.51) 30 (47.62) III 71 (58.20) 25 (39.68) V 5 (4.10) 3 (4.76) T1 23 (18.85) 12 (19.05) T2 25 (20.49) 16 (25.40) T3 74 (60.66) 33 (55.56) pN 0.33 (27.05) 29 (46.03) N0 33 (27.05) 29 (46.03) N1 56 (45.90) 17 (26.98) N2 28 (22.95) 14 (22.22) N3 27 (47.60) 20 (40.7) N2 28 (22.95) 16 (25.40) N2 28 (22.95) 16 (25.40) N2 28 (22.95) 16 (25.40) No 30 (31.97) 20 (31.75) No 89 (72.93) 16 (1	19 (15.58)	12 (19.05)	
3 54 (4.26) 19 (30.16) Lymph node 0.256 Yes 91 (74.59) 42 (66.67) No 31 (25.41) 32 (33.33) Tumor stage 0.082 I 10 (8.20) 5 (7.94) II 36 (29.51) 30 (47.62) III 36 (29.51) 30 (47.62) IV 35 (45.00) 3 (47.62) V 5 (4.10) 3 (47.62) T 23 (18.85) 12 (19.05) T 23 (18.85) 12 (19.05) T2 25 (20.49) 16 (25.40) T3 74 (60.66) 35 (55.56) pN 0.038 0.038 pN 0.038 0.038 N1 56 (45.90) 17 (26.98) N2 28 (22.95) 14 (22.20) N3 5 (4.10) 3 (4.76) Yes 28 (22.95) 16 (25.40) N4 16 (25.40) 0.031 N4 16 (25.40) 0.031 N4 16 (25.40) 0.031 No 9 (93.17) 20 (31.75) No 9 (39.37) 20 (31.75) No 9 (39.37) 20 (31.75) No 3 (86.03) 16 (25.40) <tr< td=""><td>2</td><td>49 (40.16)</td><td>32 (50.79)</td><td></td></tr<>	2	49 (40.16)	32 (50.79)	
Lymph node 0.256 Yes 91 (74.59) 42 (66.67) No 31 (25.41) 32 (33.3) Tumor stage 0.062 I 10 (8.20) 5 (7.94) III 36 (29.51) 30 (47.62) III 71 (58.20) 25 (39.68) V 5 (20.40) 3 (47.62) T1 23 (18.85) 12 (19.05) T2 25 (20.49) 16 (25.40) T3 25 (20.49) 16 (25.40) T4 23 (18.85) 12 (19.05) T5 25 (20.49) 16 (25.40) T6 25 (20.49) 16 (25.40) T3 25 (20.49) 16 (25.40) N0 33 (27.05) 29 (46.03) N1 56 (45.90) 77 (26.98) N2 28 (22.95) 14 (22.22) N3 5 (4.10) 3 (4.76) Verincutal invasion 5 (4.10) 3 (4.76) Verincutal invasion 93 (31.97) 20 (31.75) No 33 (28.03) 43 (68.2	3	54 (44.26)	19 (30.16)	
Yes 91 (74.59) 42 (66.7) No 31 (25.41) 32 (3.33) Tumor stage 0.082 I 10 (6.20) 5 (7.94) II 36 (29.51) 30 (47.62) III 36 (29.51) 30 (47.62) III 36 (29.51) 30 (47.62) IV 5 (4.10) 3 (4.76) pT 0.728 T1 23 (18.85) 12 (19.05) T2 25 (20.49) 16 (25.40) T3 24 (60.66) 35 (55.56) NO 33 (27.05) 29 (46.03) N1 5 (41.0) 3 (4.76) N2 82 (22.95) 14 (22.22) N3 5 (41.0) 3 (4.76) Perincural invasion 5 (41.0) 3 (4.76) No 3 (32.05) 16 (25.40) No 3 (32.05) 6 (25.40) No 3 (32.05) 6 (25.40) No 9 (70.95) 46 (62.90) 0.03 No 3 (32.05) 6 (25.40) 0.03 No 3 (32.05) 32 (32.07) <t< td=""><td>Lymph node</td><td></td><td></td><td>0.256</td></t<>	Lymph node			0.256
No 31 (25.41) 32 (33.3) Tumor stage 0.082 I 10 (8.20) 5 (7.94) II 36 (29.51) 30 (47.62) III 71 (58.20) 25 (39.68) pT 0.728 T1 23 (18.85) 12 (19.05) T2 25 (20.49) 16 (25.40) T3 25 (20.49) 16 (25.40) T4 23 (20.55) 0.038 pN 74 (60.66) 25 (55.56) N0 33 (27.05) 14 (22.22) N3 56 (45.90) 17 (26.88) N2 28 (22.95) 14 (22.22) N3 54 (410) 34 (.76) Perineural invasion 28 (22.95) 16 (25.40) No 94 (77.05) 47 (74.60) Vpmphovascular space invasion 99 (31.97) 20 (31.75) No 33 (27.05) 15 (23.81) TLS- 99 (72.95) 48 (76.19) TLS- 99 (72.95) 58 (47.64) Yes 58 (47.54) 32 (50.79) No 53 (25.79) 10	Yes	91 (74.59)	42 (66.67)	
Tumor stage 0.082 I 10 (8.20) 5 (7.94) II 36 (29.51) 30 (47.62) III 71 (58.20) 25 (38.68) V 5 (4.10) 3 (4.76) pT 70 (8.62) 12 (19.05) T2 25 (20.49) 16 (25.40) T3 74 (66.6) 35 (55.6) pN 0.003 3 (27.05) 29 (46.03) N1 56 (45.90) 17 (26.98) N2 28 (22.95) 14 (22.22) N3 5 (4.10) 3 (4.76) Preincural invasion 5 (4.10) 3 (4.76) Yes 28 (22.95) 16 (25.40) N0 3 (9.705) 47 (74.60) Ves 28 (22.95) 16 (25.40) N0 9 (77.05) 47 (74.60) Ves 29 (36.31) 20 (31.75) No 9 (31.97) 20 (31.75) No 3 (8.03) 43 (68.25) TLS 39 (31.97) 20 (31.75) TLS 39 (37.05) 48 (76.19) TLS 39 (27.05) 48 (76.19) TLS 39 (27.05) 48 (76.19) Recurrence 0.63 Yes 58 (47.54) 32 (50.79) <t< td=""><td>No</td><td>31 (25.41)</td><td>32 (33.33)</td><td></td></t<>	No	31 (25.41)	32 (33.33)	
I10 (8.20)5 (7.94)II36 (29.51)30 (47.62)III71 (58.20)25 (39.68)IV5 (4.10)3 (4.76)pT0.728T123 (18.85)12 (19.05)T225 (20.49)16 (25.40)T374 (60.66)35 (55.56)pN0.038N03 (2.76)29 (46.03)N156 (45.90)17 (26.98)N228 (22.95)14 (22.22)N35 (4.10)3 (4.76)Perincural invasion0.711Yes28 (22.95)16 (25.40)No94 (77.05)42 (03.15)No93 (31.97)20 (31.75)No33 (68.03)43 (68.25)TLS-90 (72.95)48 (76.19)TLS-33 (27.05)15 (23.81)Recurrence0.675Yes58 (47.54)32 (50.79)No64 (52.46)31 (49.21)Perincur91 (49.21)0.51No64 (52.66)31 (49.21)Perincur0.951No64 (52.66)31 (49.21)Perincur0.951No64 (52.66)31 (49.21)Perincur0.951No63 (36.89)23 (36.51)	Tumor stage			0.082
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		10 (8.20)	5 (7.94)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	II	36 (29.51)	30 (47.62)	
N5 (4.10)3 (4.76)pT0.728T123 (18.85)12 (19.05)T225 (20.49)T374 (60.66)35 (55.56)pN0.038NO33 (27.05)NQ29 (46.03)N156 (45.90)N228 (22.95)N35 (4.10)Yes28 (22.95)N094 (77.05)Yes39 (31.97)Yes39 (31.97)NA30 (27.05)NA30 (27.05)NA30 (27.05)NA30 (27.05)NA30 (27.05)NA30 (31.97)Yes39 (31.97)NA30 (27.05)NA30 (27	Ш	71 (58.20)	25 (39.68)	
pT 0.728 T1 23 (18.85) 12 (19.05) T2 25 (20.49) 16 (25.40) T3 74 (60.66) 35 (55.56) pN 0.038 NO 33 (27.05) 29 (46.03) N1 56 (45.90) 17 (26.98) N2 28 (22.95) 14 (22.22) N3 5 (4.10) 3 (4.76) Perineural invasion 0.711 Yes 28 (22.95) 16 (25.40) No 39 (31.97) 20 (31.75) No 39 (31.97) 20 (31.75) No 33 (68.03) 43 (68.25) TLS 39 (31.97) 20 (31.75) No 83 (27.95) 15 (23.81) Recurrence 0.634 TLS- 39 (27.95) 15 (23.81) Recurrence 0.675 Yes 58 (47.54) 32 (50.79) No 64 (52.46) 31 (49.21) Death 0.959 Yes 58 (68.68) 23 (36.51)	IV	5 (4.10)	3 (4.76)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Τα			0.728
T1T2T2 (20.63)T4 (10.65)T225 (20.49)16 (25.40)T374 (60.66)35 (55.56)pN	T1	23 (18 85)	12 (19.05)	
T3 74 (60.66) 35 (55.56) pN 0.038 N0 33 (27.05) 29 (46.03) N1 56 (45.90) 17 (26.98) N2 28 (22.95) 14 (22.22) N3 5 (4.10) 3 (4.76) Perineural invasion 0.711 Yes 28 (22.95) 16 (25.40) N0 94 (77.05) 47 (74.60) Lymphovascular space invasion 0.976 Yes 39 (31.97) 20 (31.75) No 83 (68.03) 43 (55.56) TLS+ 89 (72.95) 48 (76.19) TLS- 33 (27.05) 15 (23.81) Recurrence 0.675 Yes 58 (47.54) 32 (50.79) No 65.246() 31 (20.91) Perineurence 0.675 Yes 58 (47.54) 32 (50.79) No 65.246() 31 (20.91) Perineurence 0.959 Yes 58 (47.54) 32 (50.79) No 65.246() 31 (20.91) No 65.246() 32 (36.51) No 65.268.91 23 (36.51) No 65.268.91 23 (36.51)	T2	25 (20.49)	16 (25 40)	
N3 33 (27.05) 29 (46.03) N0 33 (27.05) 29 (46.03) N1 56 (45.90) 17 (26.98) N2 28 (22.95) 14 (22.22) N3 5 (4.10) 3 (4.76) Perineural invasion 5 (4.10) 3 (4.76) Yes 28 (22.95) 16 (25.40) N0 94 (77.05) 47 (74.60) Lymphovascular space invasion 94 (77.05) 47 (74.60) Yes 39 (31.97) 20 (31.75) No 83 (68.03) 43 (68.25) TLS 99 (72.95) 48 (76.19) TLS- 33 (27.05) 15 (23.81) Recurrence 0.675 Yes 58 (47.54) 32 (50.79) No 64 (52.46) 31 (42.21) Death 97 (29.5) 48 (76.19) No 64 (52.46) 32 (50.79) No 64 (52.46) 32 (50.79) No 64 (52.46) 32 (36.51) No 53 (36.89) 23 (36.51) No 77 (63.11) 40 (63.49)	T3	74 (60 66)	35 (55 56)	
N0 33 (27.05) 29 (46.03) N1 56 (45.90) 17 (26.98) N2 28 (22.95) 14 (22.22) N3 5 (4.10) 3 (4.76) Perineural invasion 0.711 Yes 28 (22.95) 16 (25.40) No 94 (77.05) 47 (74.60) Lymphovascular space invasion 0.976 Yes 39 (31.97) 20 (31.75) No 31 (68.03) 43 (68.25) TLS 33 (27.05) 15 (23.81) Recurrence 0.634 Yes 38 (47.54) 32 (50.79) No 64 (52.46) 31 (49.21) Death	nN	74 (00.00)	33 (33.30)	0.038
N0 35 (27.05) 25 (40.05) N1 56 (45.90) 17 (26.98) N2 28 (22.95) 14 (22.22) N3 5 (4.10) 3 (4.76) Perineural invasion 0.711 Yes 28 (22.95) 16 (25.40) No 94 (77.05) 47 (74.60) Lymphovascular space invasion 0.976 Yes 39 (31.97) 20 (31.75) No 83 (68.03) 43 (68.25) TLS 0.634 TLS+ 89 (72.95) 48 (76.19) TLS- 33 (27.05) 15 (23.81) Recurrence 0.675 Yes 58 (47.54) 32 (50.79) No 68 (47.54) 32 (36.51) Death 0.959 Yes 45 (36.89) 23 (36.51)	NO	33 (27.05)	29 (46.03)	0.050
N1 30 (4.3.6) 17 (20.30) N2 28 (22.95) 14 (22.22) N3 5 (4.10) 3 (4.76) Perineural invasion 0.711 Yes 28 (22.95) 16 (25.40) No 94 (77.05) 47 (74.60) Lymphovascular space invasion 0.976 Yes 39 (31.97) 20 (31.75) No 83 (68.03) 43 (68.25) TLS 0.634 TLS+ 89 (72.95) 48 (76.19) TLS- 33 (27.05) 15 (23.81) Recurrence 0.675 Yes 58 (47.54) 32 (50.79) No 64 (52.46) 31 (49.21) Death 0.959 Yes 45 (36.89) 23 (36.51) No 77 (63.11) 40 (63.49)	NU N1	55 (27.05)	17 (26.09)	
N2 26 (22.93) 14 (22.22) N3 5 (4.10) 3 (4.76) Perineural invasion 0.711 Yes 28 (22.95) 16 (25.40) No 94 (77.05) 47 (74.60) Lymphovascular space invasion 0.976 Yes 39 (31.97) 20 (31.75) No 83 (68.03) 43 (68.25) TLS 115/+ 33 (27.05) TLS 33 (27.05) 15 (23.81) Recurrence 0.675 Yes 58 (47.54) 32 (50.79) No 64 (52.46) 31 (49.21) Death 0.959 Yes 45 (36.89) 23 (36.51)	NO	20 (22 05)	17 (20.30)	
N3 5 (4.10) 3 (4.76) Perineural invasion 0.711 Yes 28 (22.95) 16 (25.40) No 94 (77.05) 47 (74.60) Lymphovascular space invasion 0.976 Yes 39 (31.97) 20 (31.75) No 39 (36.803) 43 (68.25) TLS 0.634 TLS- 89 (72.95) 48 (76.19) TLS- 33 (27.05) 15 (23.81) Recurrence 0.675 Yes 58 (47.54) 32 (50.79) No 64 (52.46) 31 (49.21) Death	N2	28 (22.95) F (4.10)	14(22.22)	
Yes 28 (22.95) 16 (25.40) No 94 (77.05) 47 (74.60) Lymphovascular space invasion 0.976 Yes 39 (31.97) 20 (31.75) No 39 (38.03) 43 (68.25) TLS 0.634 TLS+ 89 (72.95) 48 (76.19) TLS- 33 (27.05) 15 (23.81) Recurrence 0.675 Yes 58 (47.54) 32 (50.79) No 64 (52.46) 31 (49.21) Death	NS Devices web in which	5 (4.10)	3 (4.76)	0711
Yes 28 (22.95) 16 (25.40) No 94 (77.05) 47 (74.60) Lymphovascular space invasion 0.976 Yes 39 (31.97) 20 (31.75) No 38 (68.03) 43 (68.25) TLS 58 (47.54) 66.23 TLS- 89 (72.95) 48 (76.19) TLS- 33 (27.05) 15 (23.81) Recurrence 0.675 Yes 58 (47.54) 32 (50.79) No 64 (52.46) 31 (49.21) Death		22 (22 25)	10 (05 10)	0.711
No 94 (77.05) 47 (74.60) Lymphovascular space invasion 0.976 Yes 39 (31.97) 20 (31.75) No 83 (68.03) 43 (68.25) TLS 0.634 TLS+ 89 (72.95) 48 (76.19) TLS- 33 (27.05) 15 (23.81) Recurrence 0.675 Yes 58 (47.54) 32 (50.79) No 64 (52.46) 31 (49.21) Death 0.959 Yes 45 (36.89) 23 (36.51) No 77 (63.11) 40 (63.49)	res	28 (22.95)	16 (25.40)	
Lymphovascular space invasion 0.976 Yes 39 (31.97) 20 (31.75) No 83 (68.03) 43 (68.25) TLS 0.634 TLS+ 89 (72.95) 48 (76.19) TLS- 33 (27.05) 15 (23.81) Recurrence 0.675 Yes 58 (47.54) 32 (50.79) No 64 (52.46) 31 (49.21) Death 0.959 Yes 45 (36.89) 23 (36.51) No 77 (63.11) 40 (63.49)	NO	94 (77.05)	47 (74.60)	
Yes 39 (31.97) 20 (31.75) No 83 (68.03) 43 (68.25) TLS 0.634 TLS- 89 (72.95) 48 (76.19) TLS- 33 (27.05) 15 (23.81) Recurrence 0.675 Yes 58 (47.54) 32 (50.79) No 64 (52.46) 31 (49.21) Death 0.959 Yes 45 (36.89) 23 (36.51) No 77 (63.11) 40 (63.49)	Lymphovascular space invasion			0.976
No 83 (68.03) 43 (68.25) TLS 0.634 TLS+ 89 (72.95) 48 (76.19) TLS- 33 (27.05) 15 (23.81) Recurrence 0.675 Yes 58 (47.54) 32 (50.79) No 64 (52.46) 31 (49.21) Death 0.959 Yes 45 (36.89) 23 (36.51) No 77 (63.11) 40 (63.49)	Yes	39 (31.97)	20 (31.75)	
TLS 0.634 TLS+ 89 (72.95) 48 (76.19) TLS- 33 (27.05) 15 (23.81) Recurrence 0.675 Yes 58 (47.54) 32 (50.79) No 64 (52.46) 31 (49.21) Death 0.959 Yes 45 (36.89) 23 (36.51) No 77 (63.11) 40 (63.49)	No	83 (68.03)	43 (68.25)	
TLS+ 89 (72.95) 48 (76.19) TLS- 33 (27.05) 15 (23.81) Recurrence 0.675 Yes 58 (47.54) 32 (50.79) No 64 (52.46) 31 (49.21) Death 0.959 Yes 45 (36.89) 23 (36.51) No 77 (63.11) 40 (63.49)	TLS			0.634
TLS- 33 (27.05) 15 (23.81) Recurrence 0.675 Yes 58 (47.54) 32 (50.79) No 64 (52.46) 31 (49.21) Death 0.959 Yes 45 (36.89) 23 (36.51) No 77 (63.11) 40 (63.49)	TLS+	89 (72.95)	48 (76.19)	
Recurrence 0.675 Yes 58 (47.54) 32 (50.79) No 64 (52.46) 31 (49.21) Death 0.959 Yes 45 (36.89) 23 (36.51) No 77 (63.11) 40 (63.49)	TLS-	33 (27.05)	15 (23.81)	
Yes 58 (47.54) 32 (50.79) No 64 (52.46) 31 (49.21) Death 0.959 Yes 45 (36.89) 23 (36.51) No 77 (63.11) 40 (63.49)	Recurrence			0.675
No 64 (52.46) 31 (49.21) Death 0.959 Yes 45 (36.89) 23 (36.51) No 77 (63.11) 40 (63.49)	Yes	58 (47.54)	32 (50.79)	
Death 0.959 Yes 45 (36.89) 23 (36.51) No 77 (63.11) 40 (63.49)	No	64 (52.46)	31 (49.21)	
Yes45 (36.89)23 (36.51)No77 (63.11)40 (63.49)	Death			0.959
No 77 (63.11) 40 (63.49)	Yes	45 (36.89)	23 (36.51)	
	No	77 (63.11)	40 (63.49)	

cohort, 20 (16.4%) and 69 (56.6%) cases contained intratumoral and peritumoral TLSs, respectively (supplementary material, Figure S1C, left); in the validation cohort, 13 (20.6%) and 34 (54.0%) cases were intratumoral and peritumoral, respectively (supplementary material, Figure S1C, right).

Correlations between TLSs and tumor-infiltrating immune cells in ESCC patients

To better understand the relationship between TLSs and the tumor microenvironment, we explored the general composition of TLSs [6] in ESCC patients using traditional IHC in serial sections stained for CD45⁺ lymphocytes, $CD20^+$ B cells, $CD4^+$ T cells, $CD8^+$ T cells, and $CD11c^+$ DCs. We found that $CD20^+$ B cells tended to be located in the center of the follicle, whereas $CD4^+$ T cells, $CD8^+$ T cells, and $CD11c^+$ DCs were primarily located in the parafollicular zone (Figure 2A–E), indicating that the cellular composition of TLSs in ESCC is consistent with previous results reported in other tumors [14]. Interestingly, CD68⁺ tumor-associated macrophages (TAMs), which suppress or activate immune responses, were distributed in the center of the follicle [4] (Figure 2F). We also compared the prominent immune subsets between different TLS classifications and showed that tumors containing TLSs were infiltrated with more CD45⁺ leukocytes, CD20⁺ B cells, $CD4^+$ and $CD8^+$ T cells, and $CD11c^+$ DCs compared with tumors without TLSs. We also evaluated the CD68⁺ TAMs, and there was no observed significant difference among the two groups (Figure 2G). The same results can be seen in TLS-high/low groups (Figure 2H). We also investigated the effect of different maturation of TLSs on immune cell infiltration. However, there was no significant difference in the infiltration of the six immune cells in three types of TLS (supplementary material, Figure S2A). Additionally, we explored the effect of TLS location on infiltrating immune cells. We found increased infiltration of CD8+ T cells in peritumoral TLSs than in intratumoral TLSs (supplementary material, Figure S2B). Taken together, these results reveal that tumors positive for TLSs and with higher numbers of TLSs were infiltrated with more adaptive immune cells, the major components of TLSs.

Correlations between TLSs and clinicopathologic characteristics in ESCC patients

After screening the components of TLSs in ESCC, we further explored the correlations between TLSs and clinicopathologic characteristics (Table 2). There was no correlation between TLSs and gender, age,

smoking. drinking, tumor size. tumor site. lymphovascular space invasion, perineural invasion, or histologic grade (p > 0.05) in both the discovery and validation cohorts. The presence of TLSs correlated positively with lower recurrence (discovery cohort, p < 0.001; validation cohort, p = 0.045) and relatively well-defined favorable survival (discovery cohort, p < 0.001; validation cohort, p = 0.030). Interestingly, patients with high numbers of TLSs also had lower recurrence (discovery cohort, p = 0.019; validation cohort, p = 0.032) and death than those with low TLSs in both cohorts (discovery cohort, p = 0.003; validation cohort, p = 0.018).

Correlations between TLS and survival in ESCC patients

We explored the prognostic value of TLSs by performing Kaplan–Meier curves in ESCC patients. The median follow-up time was 29 months (range: 1–48 months). During the follow-up period, 42.6% (58 of 122) of patients relapsed and 36.9% (45 of 122) died in the discovery cohort. We observed that TLS⁺ patients had better OS (discovery cohort, p = 0.0164; validation cohort, p = 0.0130; validation cohort, p = 0.0213) compared to TLS⁻ patients (Figure 3A,B). ESCC patients in the TLS-high group had longer DFS (discovery cohort, p < 0.01; validation cohort, p < 0.05) and OS (discovery cohort, p < 0.001; validation cohort, p < 0.05) compared to patients in the TLS-low group (Figure 3C,D).

We then explored the impact of TLS maturation on prognosis. We found no significant differences in DFS and OS according to TLS phenotype in both discovery and validation cohorts (supplementary material, Figure S3A,B). This may be due to the relatively small sample size of our cohort. We further explored whether prominent immune cells of TLSs could have an impact on the prognosis of ESCC patients. Survival analysis was performed according to the IHC score of each immune cell, which was divided into two groups based on the median of levels of pre-stained immune infiltrations. Only patients with more CD20⁺ B cell infiltration had longer DFS (p = 0.0105) and OS (p = 0.0341) (Figure 4). We consider that B cells, as the main components of TLS, contribute the main function [15].

In addition, univariate and multivariate analyses of clinicopathologic features was performed on the whole series as shown in Table 3. Lymph node metastasis (discovery cohort, hazard ratio [HR] = 2.695, p = 0.009; validation cohort,



Figure 2. Serial sections of immune cells composition in TLSs. (A–F) Representative IHC image of cellular composition of TLS. (A) $CD45^+$ lymphocytes. (B) $CD20^+$ B cells. (C) $CD4^+$ T cells. (D) $CD8^+$ T cells. (E) $CD11c^+$ DCs. (F) $CD68^+$ TAMs. Different immune infiltration cells between TLS-positive and -negative patients (G) and between TLS-low and -high patients (H).

Table 2. The correlation betwe	en TLS and clii	nicopathologi	c features	n the whole	series (<i>n</i> = 18	5)						
	Discovery col	nort ($n = 122$)					Validation co	hort ($n = 63$)				
Variables	TLS+	TLS-	<i>P</i> value	TLS low	TLS high	<i>P</i> value	TLS+	TLS-	<i>P</i> value	TLS low	TLS high	<i>P</i> value
Gender Male	72 (80.90)	30 (90.91)	0.185	51 (85.00)	51 (82.26)	0.683	39 (81.25)	12 (80.00)	0.914	26 (78.79)	25 (83.33)	0.646
Female Age (vears)	17 (19.10)	3 (0.09)	0.810	9 (15.00)	11 (12.74)	0.474	9 (18.75)	3 (20.00)	0.219	7 (21.21)	5 (16.67)	0.168
09×	25 (28.09) 64 (71 01)	10 (30.30) 23 (68 70)		19 (31.67) 41 (68 23)	16 (25.81) 46 (74 10)		14 (29.17) 34 (70.82)	2 (13.33) 13 (86 67)		6 (18.18) 27 (81 82)	10 (33.33) 20 (66 67)	
Smoke		(01.00) 02	0.671			0.722			0.393	(20.10) 12	(10.00) 02	0.275
Smoking Non-smoking	42 (47.19) 47 (52 81)	17 (51.52) 16 (48 48)		30 (50.00) 30 (50.00)	29 (46.77) 33 (53 23)		22 (45.83) 26 (54 17)	5 (33.33) 10 (66 67)		12 (36.36) 21 (63 64)	15 (50.00) 15 (50.00)	
Drink	(10.20) /+	(04.04) 01	0.700			0.191	(11.70) 02		0.098	(10.00) 12		0.064
Drinking Non-drinking	37 (41.57) 52 (58 43)	15 (45.45) 18 (54 55)		22 (36.67) 38 (63 33)	30 (48.39) 32 (51 61)		21 (43.75) 27 (56.25)	3 (20.00) 12 (80.00)		9 (27.27) 24 (72 72)	15 (50.00) 15 (50.00)	
Site			0.372			0.778			0.730			0.089
Upper	7 (7.87)	1 (3.03)		3 (5.00)	5 (8.06)		8 (16.67)	2 (13.33)		4 (12.12)	6 (20.00)	
Middle	40 (44.94)	19 (57.58)		29 (48.33)	30 (48.39)		20 (41.67)	5 (33.33)		10 (30.30)	15 (50.00)	
Lower	42 (47.19)	13 (39.39)		28 (46.67)	27 (42.55)		20 (41.67)	8 (53.33)		19 (57.58)	9 (30.00)	
Size (mm)			0.864			0.461			0.565			0.572
≤40 ~ 40	42 (47.19) 47 (62 01)	15 (45.45) 10 (64 66)		26 (43.33) 24 (55.67)	31 (50.00) 21 (50.00)		20 (41.67) 20 (E0 22)	5 (33.33) 10 (66 67)		12 (36.36) 21 (62 64)	13 (43.33) 17 (66 67)	
	(10.70) /4		3660	(10.00) +0		0 63 1	(0000) 07		0100	(+0.00) 12		0000
HISTOLOGIC Grade	14 (15 73)	5 (15 15)	0.336	g (13 33)	11 (17 74)	0.631	11 (22 92)	1 (6.67)	0.180	4 (12 12)	8 (76.67)	0.338
- 0	39 (43 82)	10 (30 30)		73 (38 33)	76 (41 94)		75 (52 08)	7 (46.67)		7 (12.12) 18 (54 55)	14 (46 67)	
1 0	36 (40.45)	18 (54.55)		29 (48.33)	25 (40.32)		12 (52.00)	7 (46.67)		11 (33.33)	8 (26.67)	
Lymph node metastasis			0.264			0.350			1.000			0.593
Yes	64 (71.91)	27 (81.82)		47 (78.33)	44 (70.97)		32 (66.67)	10 (66.67)		21 (63.64)	21 (70.00)	
No	25 (28.09)	6 (18.18)		13 (21.67)	18 (29.03)		16 (33.33)	5 (33.33)		12 (36.36)	9 (30.00)	
Tumor stage			0.061			0.327			0.188			0.407
I and II	38 (42.70) E1 (E7 20)	8 (24.24) 25 (75 76)		20 (33.33) 40 (66.67)	26 (41.94) 26 (50.06)		22 (45.83) 26 (64 17)	4 (26.67) 11 (72 77)		12 (36.36) 21 (62 64)	14 (46.67) 16 (E2 22)	
Perineural invasion			0.240	(10.00) 0+		0.596	(11.70) 02	(11.01) 11	0.418	Z1 (00.04)		0.720
Yes	18 (20.22)	10 (30.30)		15 (25.00)	13 (20.97)		11 (22.92)	5 (33.33)		9 (27.27)	7 (23.33)	
No	71 (79.78)	23 (69.70)		45 (75.00)	49 (79.03)		37 (77.08)	10 (66.67)		24 (72.73)	23 (76.67)	
Lymphovascular space invasion			0.284			0.274			0.628			0.777
Yes	26 (29.21)	13 (39.39)		22 (36.67)	17 (27.42)		16 (33.33)	4 (26.67)		11 (33.33)	9 (30.00)	
No	63 (70.79)	20 (60.61)		38 (63.33)	45 (72.58)		32 (66.67)	11 (73.33)		22 (66.67)	21 (70.00)	
Recurrence			<0.001			0.019			0.045			0.032
Yes	33 (37.08)	25 (75.76)		35 (58.33)	23 (37.10)		21 (43.75)	11 (73.33)		21 (63.64)	11 (36.67)	
N0	56 (62.92)	8 (24.24)		25 (41.47)	39 (62.90)		27 (56.25)	4 (26.67)		12 (36.36)	19 (63.33)	
Death			<0.001			0.003			0.030			0.018
Yes	25 (28.09) 64 (71 91)	21 (63.64) 12 (36 36)		30 (50.00) 30 (50.00)	15 (24.19) 47 (75 81)		14 (29.17) 34 (70.83)	9 (60.00) 6 (40.00)		16 (48.48) 17 (51 52)	6 (16.17) 25 (83 33)	
IND	(1011) +0	(00.00) 21		00,000 00	4/ (10:01)		(00.01) +0	(~~~+) n		(20.10) 11	(00.00) 02	

@ 2022 Nanjing Medical University. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland and John Wiley & Sons Ltd.

J Pathol Clin Res 2022; 8: 422-435



Figure 3. Prognostic significance of TLS presence and abundance in ESCC patients. (A, B) Kaplan–Meier analysis of DFS and OS in discovery cohort (n = 122) (A) and validation cohort (n = 63) (B) according to TLS presence. (C, D) Kaplan–Meier analysis of DFS and OS in discovery cohort (n = 122) (C) and validation cohort (n = 63) (D) according to TLS abundance.

HR = 2.829, p = 0.022), tumor stage (discovery cohort, HR = 4.485, p < 0.001; validation cohort, HR = 5.847, p < 0.001), abundance (discovery cohort, HR = 0.491, p = 0.008; validation cohort, HR = 0.420, p = 0.02), and presence (discovery cohort, HR = 0.325, p < 0.001; validation cohort, HR = 0.418, p = 0.02) of TLSs were associated with DFS in ESCC. Multivariate Cox regression analyses identified tumor stage (discovery cohort, HR = 0.281, p = 0.005) and TLS presence (discovery cohort, HR = 0.384, p < 0.001; validation cohort, HR = 0.444, p = 0.032) as independent prognostic factors for DFS.

With regard to OS, univariate Cox regression analyses identified tumor stage (discovery cohort, HR = 4.017, p < 0.001; validation cohort, HR = 2.353, p = 0.012), TLS abundance (discovery cohort, HR = 0.349, p = 0.001; validation cohort, HR = 4.144, p = 0.015), and TLS presence (discovery cohort, HR = 0.281, p < 0.001; validation cohort, HR = 0.302, p = 0.006) as clinicopathologic factors that contributed to OS. Furthermore, multivariate analyses identified that only TLS presence (discovery cohort, HR = 0.293, p < 0.001; validation cohort, HR = 0.266, p = 0.003) was an independent indicator for OS. Taken together, these results suggested that the presence of TLS signified a favorable prognosis for ESCC.

Finally, we aimed to construct a nomogram, incorporating the presence of TLSs, to predict the probability of 1-, 2-, 3-, and 4-year OS, based on the multivariate Cox analyses. Then, a nomogram that



Figure 4. $CD20^+$ B cell infiltration favors a good prognosis in ESCC patients. (A, B) Kaplan–Meier analysis of DFS (A) and OS (B) in discovery cohort (n = 122) according to $CD20^+$ B cell infiltration.

© 2022 Nanjing Medical University. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland and John Wiley & Sons Ltd.

85)	
u = 1	
series	
e whole	
S in the	
and 0	
es, DFS	
feature	
hologic	
nicopat	
s of cli	
analyse	
variate	
d multi	
iate an	
. Univa	
Table 3.	

	D	scovery coh	ort ($n = 122$)		>	alidation co	hort ($n = 63$)	
	DFS		0S		DFS		SO	
Variables	HR (95% CI)	<i>P</i> value						
Univariate analysis								
Gender (male versus female)	1.366 (0.467–2.882)	0.413	1.928 (0.687–6.416)	0.213	0.970 (0.399–2.360)	0.947	1.296 (0.478–3.515)	0.61
Aqe (years) (≤60 versus >60)	1.120 (0.647–1.938)	0.686	1.598 (0.763-3.349)	0.214	1.722 (0.706–4.196)	0.232	1.617 (0.545-4.798)	0.387
Smoke (smoking versus	1.135 (0.678-1.900)	0.629	1.077 (0.583-1.987)	0.814	1.017 (0.505-2.046)	0.963	1.868 (0.760-4.589)	0.173
non-smoking)								
Drink (drinking versus	1.139 (0.680-1.909)	0.62	1.211 (0.650-2.257)	0.547	1.248 (0.601–2.592)	0.552	1.880 (0.734–4.815)	0.188
non-drinking)								
Site (upper versus middle versus lower)	2.158 (0.514-9.063)	0.293	1.267 (0.294–5.463)	0.751	1.287 (0.415–3.995)	0.662	0.980 (0.253-3.798)	0.977
	2.195 (0.523-9.233)	0.283	1.646 (0.385-7.029)	1.646	1.700 (0.568–5.090)	0.343	1.477 (0.415–5.529)	0.548
Size (mm) (≤40 versus >40)	1.652 (0.971–2.812)	0.064	1.180 (0.636–2.472)	0.6	1.385 (0.667–2.875)	0.382	1.219 (0.511–2.908)	0.656
Lymphovascular space invasion (yes versus no)	1.389 (0.812-2.373)	0.23	1.309 (0.692–2.472)	0.406	1.625 (0.730-3.621)	0.235	2.697 (0.908-8.006)	0.074
Perineural invasion (yes versus no)	1.694 (0.962-2.985)	0.068	1.610 (0.821–3.157)	0.166	1.063 (0.476–2.370)	0.882	1.043 (0.408-2.665)	0.931
Histologic grade (1 versus 2 versus 3)	3.053 (0.907-10.278)	0.072	3.702 (0.855-16.028)	0.08	4.215 (0.977-18.176)	0.054	2.281 (0.505-10.307)	0.284
	5.684 (1.744-18.524)	0.004	5.223 (1.239–22.014)	0.024	5.725 (1.277-25.654)	0.023	3.803 (0.819-17.656)	0.088
Lymph node metastasis	2.695 (1.276-5.693)	0.009	2.293 (1.023-5.141)	0.44	2.829 (1.163–6.883)	0.022	2.875 (0.967-8.544)	0.057
(yes versus no)								
Tumor stage (I and II versus III and IV)	4.485 (2.260-8.901)	< 0.001	4.017 (1.865-8.652)	< 0.001	5.847 (2.230-15.328)	<0.001	2.353 (1.205-4.596)	0.012
TLS (low versus high)	0.491 (0.289-0.832)	0.008	0.349 (0.187-0.652)	0.001	0.420 (0.201–0.874)	0.02	4.144 (1.392-12.331)	0.011
TLS (TLS+ versus TLS-)	0.325 (0.193-0.549)	< 0.001	0.281 (0.156-0.506)	< 0.001	0.418 (0.200-0.873)	0.02	0.302 (0.128–0.710)	0.006
Multivariate analysis								
TLS (TLS+ versus TLS-)	0.384 (0.225-0.657)	< 0.001	0.293 (0.162-0.530)	< 0.001	0.444 (0.212-0.931)	0.032	0.266 (0.112-0.634)	0.003
TLS (low versus high)	NA	0.985	NA	0.225	NA	0.165	NA	0.174
Tumor stage (I and II versus III and IV)	0.234 (0.116-0.473)	< 0.001	0.260 (0.120-0.561)	0.001	0.281 (0.115-0.685)	0.005	NA	0.495
Lymph node metastasis	NA	0.428	NA	NA	NA	0.086	3.297 (1.097-9.908)	0.034
(yes versus no)								
Histologic grade (1 versus 2 versus 3)	2.137 (0.627-7.291)	0.225	NA	0.899	NA	0.561	NA	NA
	4.040 (1.223-13.345)	0.022	NA	0.205	NA	0.714	NA	NA



Figure 5. Nomogram predicting the probability of 1-, 2-, 3-, 4-year OS and TLS-independent receiver operating characteristic (ROC) curve analyses in whole series. (A) Nomogram for predicting the probability of 1-, 2-, 3-, and 4-year OS for ESCC patients of the whole series. ROC curve analysis was used to compare the predictive accuracy between tumor stage (B), TLS presence (C), histologic grade (D), and nomogram (E) in 1, 2, 3, and 4 years.

integrated the tumor stage, histologic grade, and TLS presence was constructed to provide clinicians with a quantitative approach to predict the prognosis of patients with ESCC (Figure 5A). Receiver operating characteristic curve analysis was used to compare the predictive accuracy between nomogram, tumor stage, histologic grade, and TLS presence in 1, 2, 3, and 4 years (Figure 5B–E). The nomogram model suggested higher prognostic accuracy for 1-, 2-, 3-, and 4-year OS with a larger AUC.

Discussion

In this study, we explored the relationship between the presence, the abundance, the maturation, and the location of TLSs and the outcomes of patients with resected ESCC. The presence of TLSs was an effective predictor of favorable prognosis for ESCC, as was the abundance of TLSs, confirmed using both discovery and validation cohorts. Additionally, multivariate analyses identified that only TLS presence was an independent indicator compared with TLS abundance.

However, in our study, we found no correlation between the maturation or location of TLSs and the prognosis of ESCC patients. These findings provide new insights into the development of innovative prognostic markers for ESCC.

TLSs have been widely investigated by researchers and the effect of TLSs on the prognosis of many types of cancer has been reported, including lung cancer [16] and ovarian cancer [17], showing that patients with TLS-positive tumors have longer DFS and OS. However, in addition to the presence of TLSs, their impact on prognosis is also affected by the tissue of origin, location, abundance, and maturation. For example, the presence of TLSs in colorectal cancer has been associated with more advanced disease [18]. Even in the same type of cancer, Gu-Trantien et al found that CD4+ T cell immune infiltrates, principally located in TLS germinal centers, suggest a good prognosis by promoting anti-tumor immunity in breast cancer [19], while TLSs in breast cancer were associated with higher tumor grade, low representation of intratumoral immune cells, and a high frequency of lymph node metastasis, as reported by Figenschau et al [20]. It is

© 2022 Nanjing Medical University. *The Journal of Pathology: Clinical Research* published by The Pathological Society of Great Britain and Ireland and John Wiley & Sons Ltd.

important to understand whether TLSs are formed by different mechanisms and play different roles in different cancer types for its application in predicting prognosis. In our study, we found no correlation between the location of TLSs and the prognosis of ESCC patients. However, Ding et al discovered that the abundance of intratumoral TLSs was an effective predictor of favorable prognosis for intrahepatic cholangiocarcinoma, while the presence of peritumoral TLSs was significantly associated with dismal outcomes [21]. The same results were found in hepatocellular carcinoma [22] and breast cancer [11]. TLS abundance was reported to signify a favorable prognosis in human oral cancer [12], which was consistent with our results. Finally, we found no difference in prognosis based on TLSs of different maturity, although the P value of survival analysis was very close to 0.05. Although it is not clear whether the maturity of TLSs affects patient outcomes, by analyzing the prognosis of colorectal cancer, Posch et al concluded that mature TLSs containing germinal centers had more prognostic value than immature TLSs, and believed that the determination of mature TLSs in colorectal cancer had more implications for good prognosis than TLS counting alone [23]. Mature TLSs are often accompanied by the formation of germinal centers, indicating active anti-tumor immunity. Therefore, evaluation of TLS maturation in each tumor may be more accurate to determine the prognosis of cancer in the future.

To gain a better understanding of TLS in ESCC patients, we stained serial sections for the major components of TLSs. With regard to immune cell subtypes, CD45⁺ leukocytes, CD4⁺ T cells, CD8⁺ T cells, $CD20^+$ B cells, and $CD11c^+$ DCs accounted for the majority. We observed that ESCC patients with positive TLSs tended to be surrounded by more CD45⁺ leukocytes, as well as a higher number of tumor-infiltrating CD4⁺ T cells, CD8⁺ T cells CD20⁺ B cells, and $CD11c^+$ DCs. $CD8^+$ T cells play a central role in the adaptive immune response in cancer. We found increased infiltration of CD8⁺ T cells in peritumoral TLSs than in intratumoral TLSs, suggesting that peritumoral TLSs may have better ability to inhibit tumor growth. However, Calderaro et al reported that intratumoral TLSs are associated with a low risk of early recurrence of hepatocellular carcinoma [22]. On the other hand, TLSs have been reported to promote the synergistic anti-tumor effect of tumor-associated plasma cells and $CD8^+$ T cells [24]. Mature DCs can promote antigen presentation of T cells and B cells, and CD45⁺ lymphocytes participate in T cell signal transduction. Tumor-infiltrating

macrophages (CD68⁺ TAMs) are associated with tumor progression and low survival [18]. However, this study found no correlation between CD68⁺ TAMs and TLSs in tumors. Meanwhile, TLSs were mostly composed of a T cell zone in the outer layer and a B cell zone in the inner layer. CD11c⁺ DCs are present within the T cell zone, and B cells can cluster and form B cell follicles with actively replicating B cell germinal centers [25]. Then, TLSs promote effective anti-tumor immune responses by promoting local antigen presentation and lymphocyte differentiation. Mature DCs provide antigen to T cells and activate cellular immunity in the T cell region, while germinal center LAMP⁺ DCs provide antigen to B cells and induce humoral immunity. Almost all TLSs contain B cells, and high expression of $CD20^+$ B cells in the tumor microenvironment is associated with a good prognosis in most cancers such as biliary tract cancer [26] and skin cancer [27]. We also found that patients with more CD20⁺ B cell infiltration had longer DFS (p = 0.0105) and OS (p = 0.0341), indicating that B cell-related pathways may play a key role in the generation and formation of TLSs.

Finally, we integrated tumor stage, histologic grade, and the presence of TLSs to provide clinicians with a new nomogram model that may be used to predict OS for resected ESCC patients. TLSs are located in or near tumor tissue and promote lymphocyte transport and infiltration, making them an interesting target for anti-tumor immunity [28]. It is an interesting hypothesis to suggest that inducing TLS formation may also be an effective strategy for anti-tumor immunity in ESCC, given the significant association between TLSs and better prognosis. To date, several therapies targeting TLSs have been developed and have shown promising anti-tumor effects in various mouse models [29], and current cancer immune therapy such as checkpoint inhibitors may be more effective in combination with drugs that induce TLS generation. In the future, patients with immune resistance may benefit from the use of drugs inducing the formation or maturation of TLSs.

In conclusion, we have shown that the presence of TLSs is associated with longer DFS and OS, which is an independent favorable prognostic indicator for patients with ESCC undergoing surgical resection. Additionally, patients with more CD20⁺ B cell infiltration, the major component of TLSs, also have longer DFS and OS. This study reveals the correlation between TLS state and prognosis of patients with ESCC and provides a framework to better understand the components of TLSs, which provide an immune therapeutic avenue of clinical interest.

Acknowledgements

This work was supported by the grants from the National Natural Science Foundation of China (Grant Nos 82073211, 82002434, 82003106, 81902334); The Project of Invigorating Health Care through Science, Technology and Education, Jiangsu Provincial Medical Innovation Team (CXTDA2017002); The Project of Invigorating Health Care through Science, Technology and Education, Jiangsu Provincial Medical Outstanding Talent (JCRCA2016001); Young Talents Program of Jiangsu Cancer Hospital; and The General project of Cancer Hospital Affiliated to Nanjing Medical University (No. ZM201921).

Author contributions statement

RL, XH and WY contributed to sample and data acquisition and manuscript drafting. JW, YL, TZ, QM and WX offered technical support. LX, XX, GD and FJ made substantial contributions to the conception and design of the study, funding of the study, and supervision. All authors were involved in writing the paper and had final approval of the submitted and published versions.

References

- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7–30.
- Ohashi S, Miyamoto S, Kikuchi O, *et al*. Recent advances from basic and clinical studies of esophageal squamous cell carcinoma. *Gastroenterology* 2015; **149**: 1700–1715.
- Luo H, Lu J, Bai Y, *et al.* Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. *JAMA* 2021; 326: 916–925.
- 4. Sautès-Fridman C, Petitprez F, Calderaro J, *et al.* Tertiary lymphoid structures in the era of cancer immunotherapy. *Nat Rev Cancer* 2019; **19:** 307–325.
- Sautès-Fridman C, Lawand M, Giraldo NA, *et al.* Tertiary lymphoid structures in cancers: prognostic value, regulation, and manipulation for therapeutic intervention. *Front Immunol* 2016; 7: 407.
- Munoz-Erazo L, Rhodes JL, Marion VC, *et al.* Tertiary lymphoid structures in cancer – considerations for patient prognosis. *Cell Mol Immunol* 2020; **17:** 570–575.
- Hiraoka N, Ino Y, Yamazaki-Itoh R, *et al.* Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer. *Br J Cancer* 2015; **112**: 1782–1790.

- Di Caro G, Bergomas F, Grizzi F, *et al.* Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. *Clin Cancer Res* 2014; **20**: 2147–2158.
- Lin Q, Tao P, Wang J, *et al.* Tumor-associated tertiary lymphoid structure predicts postoperative outcomes in patients with primary gastrointestinal stromal tumors. *Oncoimmunology* 2020; 9: 1747339.
- 10. Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer. *Science* 2022; **375**: eabf9419.
- Sofopoulos M, Fortis SP, Vaxevanis CK, et al. The prognostic significance of peritumoral tertiary lymphoid structures in breast cancer. Cancer Immunol Immunother 2019; 68: 1733–1745.
- Li K, Guo Q, Zhang X, *et al.* Oral cancer-associated tertiary lymphoid structures: gene expression profile and prognostic value. *Clin Exp Immunol* 2020; **199:** 172–181.
- Silina K, Soltermann A, Attar FM, *et al.* Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma. *Cancer Res* 2018; **78**: 1308–1320.
- Boivin G, Kalambaden P, Faget J, *et al.* Cellular composition and contribution of tertiary lymphoid structures to tumor immune infiltration and modulation by radiation therapy. *Front Oncol* 2018; 8: 256.
- Tokunaga R, Naseem M, Lo JH, *et al.* B cell and B cell-related pathways for novel cancer treatments. *Cancer Treat Rev* 2019; 73: 10–19.
- Germain C, Gnjatic S, Tamzalit F, *et al.* Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. *Am J Respir Crit Care Med* 2014; 189: 832–844.
- Nielsen JS, Sahota RA, Milne K, *et al.* CD20+ tumorinfiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. *Clin Cancer Res* 2012; 18: 3281–3292.
- Li H, Wang J, Liu H, *et al.* Existence of intratumoral tertiary lymphoid structures is associated with immune cells infiltration and predicts better prognosis in early-stage hepatocellular carcinoma. *Aging (Albany NY)* 2020; **12:** 3451–3472.
- Gu-Trantien C, Loi S, Garaud S, *et al.* CD4(+) follicular helper T cell infiltration predicts breast cancer survival. *J Clin Invest* 2013; 123: 2873–2892.
- Figenschau SL, Fismen S, Fenton KA, *et al.* Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients. *BMC Cancer* 2015; 15: 101.
- 21. Ding GY, Ma JQ, Yun JP, *et al.* Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma. *J Hepatol* 2022; **76:** 608–618.
- 22. Calderaro J, Petitprez F, Becht E, *et al.* Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. *J Hepatol* 2019; **70**: 58–65.
- Posch F, Silina K, Leibl S, Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. *Oncoimmunology* 2018; 7: e1378844.

TLS favors outcome in resected ESCC

- Kroeger DR, Milne K, Nelson BH. Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer. *Clin Cancer Res* 2016; 22: 3005–3015.
- Fridman WH, Zitvogel L, Sautès-Fridman C, *et al.* The immune contexture in cancer prognosis and treatment. *Nat Rev Clin Oncol* 2017; 14: 717–734.
- Goeppert B, Frauenschuh L, Zucknick M, *et al.* Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. *Br J Cancer* 2013; **109**: 2665–2674.
- Garg K, Maurer M, Griss J, *et al.* Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome. *Hum Pathol* 2016; 54: 157–164.
- Maldonado L, Teague JE, Morrow MP, *et al.* Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. *Sci Transl Med* 2014; 6: 221ra213.
- Johansson-Percival A, He B, Li ZJ, *et al.* De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors. *Nat Immunol* 2017; 18: 1207–1217.

SUPPLEMENTARY MATERIAL ONLINE

Figure S1. The location of TLSs in esophageal cancer

Figure S2. Association between maturation and location of TLSs and immune infiltration

Figure S3. Prognostic significance of TLS maturation in ESCC patients

Table S1. The antibodies and conditions used in IHC in this study